DOCSLIB.ORG

Regulation of UDP- Glucuronosyltransferase 1A Genes in the Intestine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulation of UDP- Glucuronosyltransferase 1A Genes in the Intestine Regulation of UDP- glucuronosyltransferase 1A genes in the intestine by Siti Nurul Mubarokah Thesis Submitted to Flinders University for the degree of Doctor of Philosophy College of Medicine and Public Health 18 October 2018 TABLE OF CONTENTS List of Figures ................................................................................................................................ vi List of Tables ................................................................................................................................. x Summary ................................................................................................................................ xi Declaration ............................................................................................................................... xiii Acknowledgements ....................................................................................................................... xiv Publication ............................................................................................................................... xvi Conference Proceedings ............................................................................................................... xvi Scholarships and Awards in Support of This Thesis .................................................................... xviii Abbreviations ............................................................................................................................... xix CHAPTER 1. INTRODUCTION ....................................................................................................... 1 1.1 Glucuronidation and human UGTs ......................................................................................... 1 1.1.1 Glucuronidation .......................................................................................................... 1 1.1.2 Human UDP-Glucuronosyltransferase (UGT) enzymes .............................................. 3 1.1.3 The UGT gene super family ........................................................................................ 5 1.2 Expression of UGT genes: general aspects ......................................................................... 10 1.2.1 Tissue specific distribution of human UGTs .............................................................. 10 1.2.2 Constitutive and inducible regulation of UGTs .......................................................... 12 1.3 Intestinal UGT enzymes ....................................................................................................... 15 1.3.1 Intestinal UGTs in phenolic compound glucuronidation ............................................ 15 1.3.2 Intestinal microbiota and UGT activities .................................................................... 18 1.3.3 Expression of intestinal UGTs .................................................................................. 19 1.4 Intestinal development and homeostasis ............................................................................. 20 1.4.1 Intestinal development is critically regulated by homeobox factors including the master regulator CDX2 ............................................................................................. 20 1.4.2 The intestine is maintained by continual epithelial turnover that is controlled by developmental regulators. ........................................................................................ 22 1.4.3 Constitutive regulation of intestinal UGTs by CDX2 and its partners ......................... 27 1.5 In vitro models for intestinal UGT studies ............................................................................. 31 1.5.1 Caco-2 as a model for enterocytes ........................................................................... 31 1.5.2 The intestinal organoid model ................................................................................... 32 1.5.3 ‘Humanised’ UGT transgenic mouse models ............................................................ 34 1.6 UGT1A8 is the prototypical intestinal-specific UGT gene ..................................................... 36 i 1.6.1 UGT1A8 expression, activities and substrates .......................................................... 36 1.6.2 UGT1A8 polymorphisms in drug metabolism and cancer risk ................................... 38 1.6.3 UGT1A8 gene regulation .......................................................................................... 40 1.7 Project overview and experimental aims .............................................................................. 44 CHAPTER 2. MATERIALS AND GENERAL METHODS ............................................................... 46 2.1 Materials .............................................................................................................................. 46 2.1.1 Chemicals, reagents and buffers .............................................................................. 46 2.1.2 Mammalian cell lines ................................................................................................ 46 2.1.3 Expression vectors and reporters ............................................................................. 46 2.1.4 Oligonucleotides ....................................................................................................... 47 2.2 Methods ............................................................................................................................... 47 2.2.1 Mammalian cell culture, maintenance and stocks ..................................................... 47 2.2.2 Bacterial culture and stocks ...................................................................................... 47 2.2.3 Cryopreservation of cells (freezing stocks) ............................................................... 47 2.2.4 Polymerase chain reaction (PCR) amplification ........................................................ 48 2.2.5 Total RNA extraction ................................................................................................ 49 2.2.6 cDNA synthesis ........................................................................................................ 50 2.2.7 Quantification of nucleic acid (DNA or RNA) ............................................................. 50 2.2.8 Molecular cloning using restriction enzymes ............................................................. 51 2.2.9 Competent cell preparation ....................................................................................... 51 2.2.10 Plasmid DNA extraction ............................................................................................ 52 2.2.11 Agarose gel electrophoresis ..................................................................................... 52 2.2.12 DNA Sequencing ...................................................................................................... 53 2.2.13 Plasmid-DNA transfection......................................................................................... 53 2.2.14 Luciferase reporter assays ....................................................................................... 54 2.2.15 Chromatin Immunoprecipitation (ChIP) assays ......................................................... 55 2.2.16 Electrophoretic mobility shift assay (EMSA) ............................................................. 56 2.2.17 Western blotting ....................................................................................................... 57 2.2.18 Cell imaging (EVOS® FL) ......................................................................................... 58 2.2.19 Statistics ................................................................................................................... 58 CHAPTER 3. REGULATION OF INTESTINAL UGTs BY A COMBINATORIAL MECHANISM OF CDX2 AND HNF4 ................................................................................................ 59 3.1 Introduction .......................................................................................................................... 59 3.2 Methods ............................................................................................................................... 63 3.2.1 Plasmids ................................................................................................................... 63 ii 3.2.2 Mutagenesis of binding sites in UGT1A8, -1A9 and -1A10 promoter constructs ....... 63 3.2.3 Transfections of CDX2 and HNF4 expression vectors ............................................ 64 3.2.4 Chromatin Immunoprecipitation (ChIP) assays in Caco-2 cells ................................. 64 3.2.5 Non-radioactive EMSA assays in Caco-2 cells ......................................................... 64 3.2.6 CDX2 and HNF4α siRNA design and transfection .................................................... 64 3.2.7 Transcriptomic data profiling of Colon Adenocarcinoma (COAD) from The Cancer Genome Atlas (TCGA) ............................................................................................. 65 3.2.8 Oligonucleotides ....................................................................................................... 65 3.3 Results and Discussion ........................................................................................................ 67 3.3.1 CDX2 synergistically interacts with HNF4 to further induce UGT1A8 promoter activity .....................................................................................................................
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker
    Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker Author(s) 山村, 宏江 Citation 北海道大学. 博士(工学) 甲第11137号 Issue Date 2013-09-25 DOI 10.14943/doctoral.k11137 Doc URL http://hdl.handle.net/2115/77180 Type theses (doctoral) File Information Hiroe_Yamamura.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Doctoral Thesis Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent-Responsive Biomarker Hiroe Hara-Yamamura Acknowledgement My doctoral research works presented here cannot be completed without a numerous number of tangible and intangible supports from my peers, my supervisor, instructors, friends, and family. I would first express my deepest gratitude to Prof. Satoshi OKABE for his technical advices and crisp ideas which often came to break the deadlock of my research progress, and for continued provision of another chance to me, even in the least fruitful season. Indeed, my three years in Prof. OKABE’s lab was “luxuri- ous” time in my life with a lot of supports, encouragements, and chances. In addition, I appreciate both Prof. Daisuke SANO and Dr. Satoshi ISHII for offering their insights on my experimental design and data analysis as well as giving me words of encouragements from time to time. Also, thank you to Prof. Takashi KUSUI from Toyama Prefectural University for his assistance to bioassay techniques and valuable discussion dur- ing my 1st year and 2nd year evaluation presentations. Furthermore, I would like to express my gratitude to specific efforts kindly provide by: Mr. Kenzo Kudo, Prof.
    [Show full text]
  • Novel Copy-Number Variations in Pharmacogenes Contribute to Interindividual Differences in Drug Pharmacokinetics
    ORIGINAL RESEARCH ARTICLE © American College of Medical Genetics and Genomics Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics María Santos, MSc1, Mikko Niemi, PhD2, Masahiro Hiratsuka, PhD3, Masaki Kumondai, BSc3, Magnus Ingelman-Sundberg, PhD4, Volker M. Lauschke, PhD4 and Cristina Rodríguez-Antona, PhD1,5 Purpose: Variability in pharmacokinetics and drug response is of the genes studied. We experimentally confirmed novel deletions shaped by single-nucleotide variants (SNVs) as well as copy- in CYP2C19, CYP4F2, and SLCO1B3 by Sanger sequencing and number variants (CNVs) in genes with importance for drug validated their allelic frequencies in selected populations. absorption, distribution, metabolism, and excretion (ADME). Conclusion: CNVs are an additional source of pharmacogenetic While SNVs have been extensively studied, a systematic assessment variability with important implications for drug response and of the CNV landscape in ADME genes is lacking. personalized therapy. This, together with the important contribu- Methods: We integrated data from 2,504 whole genomes from the tion of rare alleles to the variability of pharmacogenes, emphasizes 1000 Genomes Project and 59,898 exomes from the Exome the necessity of comprehensive next-generation sequencing–based Aggregation Consortium to identify CNVs in 208 relevant genotype identification for an accurate prediction of the genetic pharmacogenes. variability of drug pharmacokinetics. Results: We describe novel exonic deletions
    [Show full text]
  • Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics
    ORIGINAL RESEARCH published: 03 February 2017 doi: 10.3389/fphar.2017.00023 Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics Michèle Rouleau, Yannick Audet-Delage, Sylvie Desjardins, Mélanie Rouleau, Camille Girard-Bock and Chantal Guillemette * Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec, QC, Canada The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs) significantly influences the bioavailability and biological responses of endogenous molecule substrates and xenobiotics including drugs. UGTs participate in the regulation of cellular homeostasis by limiting stress induced by toxic molecules, and by Edited by: controlling hormonal signaling networks. Glucuronidation is highly regulated at genomic, Yuji Ishii, transcriptional, post-transcriptional and post-translational levels. However, the UGT Kyushu University, Japan protein interaction network, which is likely to influence glucuronidation, has received Reviewed by: little attention. We investigated the endogenous protein interactome of human UGT1A Ben Lewis, Flinders University, Australia enzymes in main drug metabolizing non-malignant tissues where UGT expression is Shinichi Ikushiro, most prevalent, using an unbiased proteomics approach. Mass spectrometry analysis Toyama Prefectural University, Japan of affinity-purified UGT1A enzymes and associated protein complexes in liver,
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]
  • Endogenous Protein Interactome of Human
    Human UGT1A interaction network 1 Endogenous protein interactome of human UDP- 2 glucuronosyltransferases exposed by untargeted proteomics 3 4 5 Michèle Rouleau, Yannick Audet-Delage, Sylvie Desjardins, Mélanie Rouleau, Camille Girard- 6 Bock and Chantal Guillemette* 7 8 Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Centre 9 Hospitalier Universitaire (CHU) de Québec Research Center and Faculty of Pharmacy, Laval 10 University, G1V 4G2, Québec, Canada 11 12 13 14 15 *Corresponding author: 16 Chantal Guillemette, Ph.D. 17 Canada Research Chair in Pharmacogenomics 18 Pharmacogenomics Laboratory, CHU de Québec Research Center, R4720 19 2705 Boul. Laurier, Québec, Canada, G1V 4G2 20 Tel. (418) 654-2296 Fax. (418) 654-2298 21 E-mail: [email protected] 22 23 24 25 26 27 28 29 30 31 32 Running title: Human UGT1A interaction network 33 1 Human UGT1A interaction network 1 Number of: Pages: 26 2 Tables: 2 3 Figures: 5 4 References: 62 5 Supplemental Tables: 7 6 Supplemental Figures: 5 7 8 Number of words: Total: 7882 9 Abstract: 229 10 Introduction: 549 11 Results: 1309 12 Discussion: 1403 13 Body Text: 3261 14 15 16 17 18 Abbreviations: AP: affinity purification; UGT, UDP-glucuronosyltransferases; IP, immuno- 19 precipitation; PPIs, protein-protein interactions; UDP-GlcA, Uridine diphospho-glucuronic acid; 20 ER, endoplasmic reticulum; MS, mass spectrometry. 21 22 Keywords: UGT; Proteomics; Protein-protein interaction; Affinity purification; Mass 23 spectrometry; Metabolism; Human tissues; 24 2 Human UGT1A interaction network 1 ABSTRACT 2 3 The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs) 4 significantly influences the bioavailability and biological responses of endogenous molecule 5 substrates and xenobiotics including drugs.
    [Show full text]
  • Exploration on Atypical Kinetics of Ugt1a1 and Ugt1a4
    EXPLORATION ON ATYPICAL KINETICS OF UGT1A1 AND UGT1A4 A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY JIN ZHOU IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Dr. Rory P. Remmel, Adviser Dr. Timothy S. Tracy, Co-adviser August 2010 i Acknowledgements I wish to express my sincere appreciation and gratitude to Dr. Rory Remmel and Dr. Timothy Tracy for their guidance over the years of my graudate training. Dr. Remmel and Dr. Tracy both have contributed tremendously to my scientific and personal life. I also wish to thank the members of the examining committee: Dr. Stephen Hecht, Dr. Shana Sturla, and Dr. Chengguo Xing for their assistance and constructive suggestions. I would like to thank everyone who has helped me over the past few years, particularly various members in Drug Design Center, Dr. Peter Villalta in Cancer Center, the faculty and staff of the Department of Medicinal Chemistry, and the members of the Drug Metabolism journal club. Finally, I would like to thank Bristol-Myers Squibb and NIH for their financial support of this project. ii THIS THESIS IS DEDICATED TO MY LOVING HUSBAND AND PARENTS iii Abstract Atypical (non-Michaelis-Menten) kinetics confound straightforward in vitro-in vivo extrapolations on clearance and inhibition potentials of new chemical entities. However, unlike cytochrome P450s, studies on atypical kinetics of uridine 5'- diphospho-glucuronosyltransferases (UGTs) are much less prevalent. With the use of model substrates, the atypical kinetics of two important glucuronidation enzymes, UGT1A1 and UGT1A4, were explored. In Chapter 2 (Part I), two positional isomers dihydrotestosterone (DHT) and trans-androsterone (t-AND) were used as probe substrates and their glucuronidation kinetics with recombinant UGT1A4 were evaluated alone and in the presence of a UGT1A4 substrate (tamoxifen (TAM) or lamotrigine (LTG)).
    [Show full text]
  • Program in Human Neutrophils Fails To
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 is online at: average * The Journal of Immunology Anaplasma phagocytophilum , 20 of which you can access for free at: 2005; 174:6364-6372; ; from submission to initial decision 4 weeks from acceptance to publication J Immunol doi: 10.4049/jimmunol.174.10.6364 http://www.jimmunol.org/content/174/10/6364 Insights into Pathogen Immune Evasion Mechanisms: Fails to Induce an Apoptosis Differentiation Program in Human Neutrophils Dori L. Borjesson, Scott D. Kobayashi, Adeline R. Whitney, Jovanka M. Voyich, Cynthia M. Argue and Frank R. DeLeo cites 28 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2005/05/03/174.10.6364.DC1 This article http://www.jimmunol.org/content/174/10/6364.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* • Why • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Insights into Pathogen Immune Evasion Mechanisms: Anaplasma phagocytophilum Fails to Induce an Apoptosis Differentiation Program in Human Neutrophils1 Dori L.
    [Show full text]
  • Human Udp-Glucuronosyltransferase, Ugt1a8, Glucuronidates Dihydrotestosterone to a Monoglucuronide and Further to a Structurally Novel Diglucuronide
    0090-9556/06/3407-1102–1108$20.00 DRUG METABOLISM AND DISPOSITION Vol. 34, No. 7 Copyright © 2006 by The American Society for Pharmacology and Experimental Therapeutics 9621/3119192 DMD 34:1102–1108, 2006 Printed in U.S.A. HUMAN UDP-GLUCURONOSYLTRANSFERASE, UGT1A8, GLUCURONIDATES DIHYDROTESTOSTERONE TO A MONOGLUCURONIDE AND FURTHER TO A STRUCTURALLY NOVEL DIGLUCURONIDE Takahiro Murai, Naozumi Samata, Haruo Iwabuchi, and Toshihiko Ikeda Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan Received February 3, 2006; accepted March 29, 2006 ABSTRACT: We identified human UDP-glucuronosyltransferase (UGT) isoforms trointestinal UGT, and to a lesser extent with UGT1A1 and UGT1A9. responsible for producing dihydrotestosterone (DHT) diglucu- In contrast, the activity of DHT monoglucuronidation was high and ronide, a novel glucuronide in which the second glucuronosyl moi- was found in UGT2B17, UGT2B15, UGT1A8, and UGT1A4 in de- Downloaded from ety is attached at the C2؅ position of the first glucuronosyl moiety, scending order. Among the 12 UGT isoforms tested, only UGT1A8 leading to diglucuronosyl conjugation of a single hydroxyl group of was capable of producing DHT diglucuronide from DHT. The ki- DHT at the C17 position. Incubation of the DHT monoglucuronide netics of DHT diglucuronidation by microsomes from human liver with 12 cDNA-expressed recombinant human UGT isoforms and and intestine fitted the Michaelis-Menten model, and the Vmax/Km uridine 5؅-diphosphoglucuronic acid resulted in a low but measur-
    [Show full text]
  • Glucuronidation of Thyroxine in Human Liver, Jejunum, and Kidney Microsomes
    0090-9556/07/3509-1642–1648$20.00 DRUG METABOLISM AND DISPOSITION Vol. 35, No. 9 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 16097/3247781 DMD 35:1642–1648, 2007 Printed in U.S.A. Glucuronidation of Thyroxine in Human Liver, Jejunum, and Kidney Microsomes Hiroyuki Yamanaka, Miki Nakajima, Miki Katoh, and Tsuyoshi Yokoi Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan Received April 3, 2007; accepted June 19, 2007 ABSTRACT: Glucuronidation of thyroxine is a major metabolic pathway facili- ine glucuronosyltransferase activity in microsomes from 12 human tating its excretion. In this study, we characterized the glucu- livers was significantly correlated with bilirubin O-glucuronosyl- p < 0.001) and estradiol 3-O-glucuronosyl- Downloaded from ,0.855 ؍ ronidation of thyroxine in human liver, jejunum, and kidney micro- transferase (r ,p < 0.0001) activities catalyzed by UGT1A1 ,0.827 ؍ somes, and identified human UDP-glucuronosyltransferase (UGT) transferase (r isoforms involved in the activity. Human jejunum microsomes indicating that the activity in human liver is mainly catalyzed by ␮ ␮ showed a lower Km value (24.2 M) than human liver (85.9 M) and UGT1A1. Kinetic and inhibition analyses suggested that the thy- kidney (53.3 ␮M) microsomes did. Human kidney microsomes roxine glucuronidation in human jejunum microsomes was mainly showed a lower Vmax value (22.6 pmol/min/mg) than human liver catalyzed by UGT1A8 and UGT1A10 and to a lesser extent by (133.4 pmol/min/mg) and jejunum (184.6 pmol/min/mg) micro- UGT1A1, and the activity in human kidney microsomes was mainly dmd.aspetjournals.org somes did.
    [Show full text]
  • Bisphenol Aassociated Alterations in the Expression and Epigenetic
    Environmental and Molecular Mutagenesis 55:184^195 (2014) Research Article Bisphenol A-Associated Alterations in the Expression and Epigenetic Regulation of Genes Encoding Xenobiotic Metabolizing Enzymes in Human Fetal Liver Muna S. Nahar,1 Jung H. Kim,1 Maureen A. Sartor,2 and Dana C. Dolinoy1* 1Department of Environmental Health Sciences, University of Michigan, Ann Arbor, Michigan 2Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan Alterations in xenobiotic metabolizing enzyme were evaluated in silico, putative binding sites (XME) expression across the life course, along for the E-twenty-six (ETS) and activator protein1 with genetic, nutritional, and environmental reg- (AP1) related transcription factor families were ulation, can influence how organisms respond identified and unique to 97% of all candidate to toxic insults. In this study, we investigated transcripts. Interestingly, many ETS binding sites the hypothesis that in utero exposure to the contain cytosine-guanine dinucleotides (CpGs) endocrine active compound, bisphenol A (BPA), within their consensus sequences. Thus, quantita- influences expression and epigenetic regulation tive analysis of CpG methylation of three candi- of phase I and II XME genes during develop- date genes was conducted across n 5 50 ment. Using healthy 1st to 2nd trimester human samples. Higher BPA levels were associated fetal liver specimens quantified for internal BPA with increased site-specific methylation at levels, we examined XME gene expression COMT
    [Show full text]